Related Experiment Videos
Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A
F Heinen1, J Wissel, A Philipsen
1Department of Neuropediatrics, University Hospital Freiburg, Germany.
Insights
Botulinum toxin A effectively treats pediatric focal motor issues like dystonia and spasticity. This safe treatment improves joint mobility and daily function in children with muscular hyperactivity.
Area of Science:
- Neurology
- Pediatrics
- Pharmacology
Background:
- Focal motor problems in children, including dystonia and spasticity, significantly impact daily activities and care.
- Botulinum toxin A is a therapeutic agent used to manage muscle hyperactivity.
Purpose of the Study:
- To evaluate the therapeutic efficacy and safety of botulinum toxin A in pediatric patients with various focal motor disorders.
- To assess the impact of treatment on joint mobility and functional outcomes.
Main Methods:
- A cohort of 28 pediatric patients (6 months to 18 years) with cervical dystonia, adductor hip spasm, spastic drop foot, or other focal motor issues received botulinum toxin A injections.
- The mean administered dose was 22 U/kg body weight.
- Outcomes including muscular hyperactivity, joint mobility, functional benefits, and adverse events were monitored over 12-64 months.
Main Results:
- Significant reduction in muscular hyperactivity and increased joint mobility were observed in patients with dystonic conditions (p < 0.0001) and spastic adductor spasms (p < 0.0002).
- Improved joint mobility led to significant benefits in daily activities and nursing care for affected children.
- Adverse events were minimal, including local paresis (1/28), local hematoma (1/28), and one case of secondary non-response. No other adverse reactions were recorded.
Conclusions:
- Botulinum toxin A is an effective and safe therapeutic option for pediatric patients experiencing focal motor problems due to dystonic or spastic muscular hyperactivity.
- The treatment offers significant functional improvements, enhancing quality of life for children with these conditions.
Abstract:
Therapeutic effect of botulinum toxin A was studied in a group of pediatric patients (n = 28) aged between 6 months and 18 years. The patients were diagnosed with cervical dystonia (n = 6), adductor spasm of the hip (n = 8), spastic drop foot (n = 7) and various other focal motor problems associated with spastic muscular hyperactivity (n = 7). The mean dose of botulinum toxin A (Dysport) used to inject into the affected muscle was 22 U/kg body weight. Reduced muscular hyperactivity with a significant increase in joint mobility was achieved for dystonic (p < 0.0001) as well as for spastic conditions in patients with adductor spasm (p < 0.0002). For these patients the improved joint mobility represented a significant benefit for both daily activities and nursing care. Local paresis and local hematoma were observed in 1/28 and 1/28 patients, respectively; 1/28 patients developed a secondary non-response. However, apart from these side effects, no other adverse reactions to botulinum toxin A treatment were recorded during the treatment and observation period (12-64 months). Our results suggest that botulinum toxin A represents an effective and safe therapeutic substance for the treatment of pediatric patients suffering of focal motor problems due to dystonic or spastic muscular hyperactivity.